According to CoinMeta, recently, the National Medical Products Administration approved the marketing of Boji Ailun Sai Injection (trade name: Saibo Hua) submitted by Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. for the treatment of adult patients with relapsed or refractory large B-cell lymphoma who have received second-line or higher systemic therapy, including diffuse large B-cell lymphoma non-specific type, grade 3b follicular lymphoma, and high-grade B-cell lymphoma. The launch of this product provides new treatment options for affected patients.